Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure.

  title={Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure.},
  author={Laurie L. Baggio and Qingling Huang and Theodore J. Brown and Daniel J. Drucker},
  volume={127 2},
BACKGROUND & AIMS Gut-derived peptides including ghrelin, cholecystokinin (CCK), peptide YY (PYY), glucagon-like peptide (GLP-1), and GLP-2 exert overlapping actions on energy homeostasis through defined G-protein-coupled receptors (GPCRs). The proglucagon-derived peptide (PGDP) oxyntomodulin (OXM) is cosecreted with GLP-1 and inhibits feeding in rodents and humans; however, a distinct receptor for OXM has not been identified. METHODS We examined the mechanisms mediating oxyntomodulin action… 

Figures from this paper

The glucagon-like peptide-1 receptor agonist oxyntomodulin enhances beta-cell function but does not inhibit gastric emptying in mice.

The proglucagon gene gives rise to multiple peptides that play diverse roles in the control of energy intake, gut motility, and nutrient disposal. Glucagon-like peptide-1 (GLP-1), a 30-amino-acid

Oxyntomodulin Differentially Affects Glucagon-Like Peptide-1 Receptor β-Arrestin Recruitment and Signaling through Gα

Bioluminescence resonance energy transfer2 assays are applied to measure agonist-induced recruitment of βarrestins and G-protein-coupled receptor kinase (GRK) 2 to the GLP-1 receptor in addition to traditional measurements of second messenger generation to suggest that oxyntomodulin and glucagon are biased ligands on the GLp-1 receptors.

Effects of glucagon-like peptide 1 and oxyntomodulin on neuronal activity of ghrelin-sensitive neurons in the hypothalamic arcuate nucleus.

It is demonstrated that GLP-1 and OXM directly and similarly alter neuronal activity in the ARC, probably via a common GLp-1R-mediated mechanism, suggesting the existence of a common mode of action for these hormones.

Differential effects of oxyntomodulin and GLP-1 on glucose metabolism.

Activation of the GCGR seems to partially attenuate the acute beneficial effects on glucose and contributes to the insulinotropic action of oxyntomodulin.

Oxyntomodulin increases intrinsic heart rate in mice independent of the glucagon-like peptide-1 receptor.

Multiple modes of action of OXM are suggested: 1) it directly elevates murine intrinsic HR through a GLP-1R-independent mechanism, perhaps via the glucagon receptor or an unidentified OXM receptor, and 2) it lowers food intake, activity, and Tb in aGLP- 1R-dependent fashion.

Differences in the Central Anorectic Effects of Glucagon-Like Peptide-1 and Exendin-4 in Rats

Data suggest that although GLP-1rs are required for the actions of Ex4, there appear to be key differences in how Glucagon-like peptide and Ex4 interact with central nervous system GLp-1r and in how Ex4 interacts withGLP- 1r in the brain versus the periphery.

The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice

Potentiation of endogenous incretin action via DPP-4 inhibition or pharmacological augmentation of GLP-1R signalling reduces intestinal secretion of triacylglycerol, cholesterol and ApoB-48 and abolished the hypolipidaemic effect of sitagliptin.

Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice

Sustained GLP1R/GCGR dual agonism reverses obesity in DIO mice and is a novel therapeutic approach to the treatment of obesity.

A novel long-acting oxyntomodulin analogue eliminates diabetes and obesity in mice.




A role for glucagon-like peptide-1 in the central regulation of feeding

It is reported here that intracerebroventricular (ICV) GLP-1 powerfully inhibits feeding in fasted rats, and this findings suggest that central GLp-1 is a new physiological mediator of satiety.

Oxyntomodulin: a cAMP-dependent stimulus of rat parietal cell function via the receptor for glucagon-like peptide-1 (7-36)NH2.

It is concluded that, by interacting with parietal cell receptors for GLP-1 (7-36)NH2, oxyntomodulin, but notGLP-2, directly stimulates H+ production by activating the adenylate cyclase.

Minireview: the glucagon-like peptides.

The actions of these peptides on nutrient absorption and energy homeostasis and the efficacy of GLP-1 andGLP-2 in animal models of diabetes and intestinal diseases, respectively, suggest that analogs ofThese peptides may be clinically useful for the treatment of human disease.

Biological actions and therapeutic potential of the glucagon-like peptides.

Inhibitors of DP IV activity, or DP IV-resistant glucagon-like peptide analogues, may be alternative therapeutic approaches for treatment of human diseases.

Peripheral oxyntomodulin reduces food intake and body weight gain in rats.

It is reported that peripheral (ip) administration of OXM dose-dependently inhibited both fast-induced and dark-phase food intake without delaying gastric emptying and there was a significant increase in c-fos immunoreactivity in the arcuate nucleus (ARC).

The proglucagon-derived peptide, glucagon-like peptide-2, is a neurotransmitter involved in the regulation of food intake

Pharmacological and behavioral studies confirmed that glucagon-like-peptide-2 signaling is a specific transmitter inhibiting rodent feeding behavior and with potential long-term effects on body weight homeostasis.

Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats.

The present series of experiments show that GLP-1 is fully capable of inhibiting food intake in rats via a peripherally accessible site and may prove efficient as weight-reducing therapeutic agents for overweight patients with type 2 diabetes.